A Pilot Open Labeled Study of Tacrolimus in Alzheimer's Disease.
Primary Purpose
Alzheimer Disease, Mild Cognitive Impairment
Status
Withdrawn
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Tacrolimus
Sponsored by
About this trial
This is an interventional treatment trial for Alzheimer Disease
Eligibility Criteria
Inclusion Criteria:
Study subjects meeting all of the following criteria will be allowed to enroll in the study:
- Age 55-85 inclusive, male or female.
- Diagnosis of MCI or dementia due to AD as shown by positive AD biomarker (CSF or neuroimaging).
- Education level, English language skills and literacy indicates subject will be able to complete all assessments.
- Willing and able to complete all assessment and study procedures, including phlebotomies, lumbar punctures, MRIs, neurocognitive testing.
- Subject has a study partner with at least two days of contact per week and willingness to assist with subject's research activities.
- If on cholinesterase inhibitor and/or memantine, doses are stable for 3 months prior to baseline.
Exclusion Criteria:
Subjects meeting any of the following criteria during the screening evaluation will be excluded:
- Allergy or hypersensitivity to tacrolimus.
- Any specific CNS disease other than suspected AD, such as major clinical stroke, brain tumor, normal pressure hydrocephalus, multiple sclerosis, significant head trauma with persistent neurological of cognitive deficits or complaints, Parkinson's disease, frontotemporal dementia, and/or other neurodegenerative diseases.
- Any significant systemic illness or clinically significant unstable medical condition that could affect subject safety or compliance with the study; including but not limited to any active infection, active malignancy except non-melanomatous skin cancers, cirrhosis, active hepatitis, uncontrolled diabetes (A1c >8), AIDS, common variable immunodeficiency, conditions treated with biologics, uncontrolled hypertension, chronic kidney disease with an eGFR <45 ml/min, Platelets < 100K, Hgb <9.
- History of alcohol or other substance abuse or dependence with the past two years.
- Major active psychiatric illness (e.g. depression, bipolar disorder, obsessive compulsive disorder, schizophrenia) within the previous year.
- Current suicidal ideation or history of suicide attempt.
Contraindications to undergo MRI studies:
- History of a cardiac pacemaker or pacemaker wires,
- Metallic particles in the body,
- Vascular clips in the head,
- Prosthetic heart valves, or
- Severe claustrophobia impeding ability to participate in an imaging study.
MRI findings that show one or more of the following:
- More than 4 incidental microhemorrhages,
- Incidental lacunar infarcts with attributable signs or symptoms and with history of stroke,
- Incidental meningiomas with attributable signs or symptoms, or
- Newly recognized meningioma.
- Laboratory abnormalities in B12, TSH, or other common laboratory parameters that may contribute to cognitive dysfunction.
- Laboratory abnormalities in PT-INR, CBC, electrolytes, magnesium, LFTs, BUN, Cr or others, or abnormalities in ECG posing risk to treatment with tacrolimus.
- Current use of medications with psychoactive properties (e.g., anticholinergics, antihistamines, antipsychotics, sedative hypnotics, anxiolytics) that may deleteriously affect cognition in the judgement of the investigator.
- Current use of medications that interact with tacrolimus (protease inhibitors, macrolides, rifampin, barbiturates, phenytoin, or azoles).
- Inability to avoid any dietary supplements that could interact with tacrolimus metabolism.
- Inability to avoid grapefruit and grapefruit juice.
- Use of other small molecule or device-based investigational agents one month prior to entry and for the duration of the trial; or participation in any immunotherapy clinical trial within three months prior to baseline visit.
- Discontinuation of cholinesterase inhibitor or memantine within one month (28 days) prior to baseline visit.
Females who are pregnant, lactating or of child-bearing potential
-
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Low Serum Level
High Serum Level
Arm Description
Stable Blood Tacrolimus of 2-5 ng/ml.
Stable Blood Tacrolimus of 5.1-10 ng/ml.
Outcomes
Primary Outcome Measures
CSF biomarkers of target engagement, AD pathology, and neurodegeneration
Evaluate effect of tacrolimus on molecular markers of target engagement (calcineurin/NFAT mediated inflammatory markers IL-2, IL-6, IFNβ and YKL-40), AD pathology (amyloid-β, tau, phospho-tau) and neurodegeneration (neurofilament-light, neurogranin). We will measure change from baseline in all CSF biomarkers following 12 weeks of steady treatment.
Secondary Outcome Measures
Blood biomarkers of target engagement, AD pathology, and neurodegeneration.
Evaluate effect of tacrolimus on molecular markers of target engagement (calcineurin/NFAT mediated inflammatory markers IL-2, IL-6, IFNβ and YKL-40), AD pathology (amyloid-β, tau, phospho-tau) and neurodegeneration (neurofilament-light, neurogranin). We will measure change from baseline in all blood biomarkers following 12 weeks of steady treatment.
Structural neuroimaging of Hippocampal volume.
Evaluate effect of tacrolimus on size of different brain regions using Magnetic Resonance Imaging (MRI). We will measure change from baseline after 12 weeks of treatment.
Functional neuroimaging of default mode network connectivity.
Evaluate effect of tacrolimus on blood flow to different brain regions using functional MRI (fMRI). We will measure change from baseline after 12 weeks of treatment.
Electroencephalograms (EEG) spectral power
Evaluate effect of tacrolimus on resting state EEG frequency using the linear power spectral density technique. We will measure change from baseline after 12 weeks of treatment.
Montreal Cognitive Assessment (MoCA)
Evaluate effect of tacrolimus on major domains of cognition (score range 0-30, high is better). We will measure change from baseline after 12 weeks of treatment.
Neuropsychiatric Inventory Questionnaire (NPIQ)
Evaluate effect of tacrolimus on neuropsychiatric symptoms as rated by a study partner/informant (score range 0-80, high is worse). We will measure change from baseline after 4, 8, and 12 weeks of treatment.
Functional Activities Questionnaire (FAQ)
Evaluate effect of tacrolimus on ability to daily functional ability as reported by study partner/informant (score range (0-30, low is better). We will measure change from baseline after 4, 8, and 12 weeks of treatment.
Repeated Battery for the Assessment of Neuropsychological Status
Evaluate the effect of tacrolimus on several domains of cognitive function (score range 40-160, higher is better). We will measure change from baseline after 4, 8, and 12 weeks of treatment.
Full Information
NCT ID
NCT04263519
First Posted
January 23, 2020
Last Updated
September 21, 2021
Sponsor
Massachusetts General Hospital
1. Study Identification
Unique Protocol Identification Number
NCT04263519
Brief Title
A Pilot Open Labeled Study of Tacrolimus in Alzheimer's Disease.
Official Title
A Pilot Open Labeled Study of Tacrolimus to Assess it's Effects on Bio-markers of Mild Cognitive Impairment and Alzheimer's Disease
Study Type
Interventional
2. Study Status
Record Verification Date
September 2021
Overall Recruitment Status
Withdrawn
Why Stopped
Covid restrictions
Study Start Date
December 1, 2021 (Anticipated)
Primary Completion Date
December 1, 2022 (Anticipated)
Study Completion Date
January 1, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Massachusetts General Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
A Pilot open labeled study of Tacrolimus in Alzheimer's Disease.
Detailed Description
This study will investigate the neurobiological effect of tacrolimus in persons with MCI and dementia due to AD by measuring biomarkers of target engagement in immune response, amyloid-b, tau and neurodegeneration in CSF, functional connectivity with MRI and EEG, and cognition. Study objectives include:
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alzheimer Disease, Mild Cognitive Impairment
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Low Serum Level
Arm Type
Active Comparator
Arm Description
Stable Blood Tacrolimus of 2-5 ng/ml.
Arm Title
High Serum Level
Arm Type
Active Comparator
Arm Description
Stable Blood Tacrolimus of 5.1-10 ng/ml.
Intervention Type
Drug
Intervention Name(s)
Tacrolimus
Intervention Description
Oral Immunosuppressant
Primary Outcome Measure Information:
Title
CSF biomarkers of target engagement, AD pathology, and neurodegeneration
Description
Evaluate effect of tacrolimus on molecular markers of target engagement (calcineurin/NFAT mediated inflammatory markers IL-2, IL-6, IFNβ and YKL-40), AD pathology (amyloid-β, tau, phospho-tau) and neurodegeneration (neurofilament-light, neurogranin). We will measure change from baseline in all CSF biomarkers following 12 weeks of steady treatment.
Time Frame
Baseline and 12 weeks
Secondary Outcome Measure Information:
Title
Blood biomarkers of target engagement, AD pathology, and neurodegeneration.
Description
Evaluate effect of tacrolimus on molecular markers of target engagement (calcineurin/NFAT mediated inflammatory markers IL-2, IL-6, IFNβ and YKL-40), AD pathology (amyloid-β, tau, phospho-tau) and neurodegeneration (neurofilament-light, neurogranin). We will measure change from baseline in all blood biomarkers following 12 weeks of steady treatment.
Time Frame
Baseline and 12 weeks
Title
Structural neuroimaging of Hippocampal volume.
Description
Evaluate effect of tacrolimus on size of different brain regions using Magnetic Resonance Imaging (MRI). We will measure change from baseline after 12 weeks of treatment.
Time Frame
Baseline and 12 weeks
Title
Functional neuroimaging of default mode network connectivity.
Description
Evaluate effect of tacrolimus on blood flow to different brain regions using functional MRI (fMRI). We will measure change from baseline after 12 weeks of treatment.
Time Frame
Baseline and 12 weeks
Title
Electroencephalograms (EEG) spectral power
Description
Evaluate effect of tacrolimus on resting state EEG frequency using the linear power spectral density technique. We will measure change from baseline after 12 weeks of treatment.
Time Frame
Baseline and 12 weeks
Title
Montreal Cognitive Assessment (MoCA)
Description
Evaluate effect of tacrolimus on major domains of cognition (score range 0-30, high is better). We will measure change from baseline after 12 weeks of treatment.
Time Frame
Baseline and 12 weeks
Title
Neuropsychiatric Inventory Questionnaire (NPIQ)
Description
Evaluate effect of tacrolimus on neuropsychiatric symptoms as rated by a study partner/informant (score range 0-80, high is worse). We will measure change from baseline after 4, 8, and 12 weeks of treatment.
Time Frame
Baseline, 4 weeks, 8 weeks and 12 weeks
Title
Functional Activities Questionnaire (FAQ)
Description
Evaluate effect of tacrolimus on ability to daily functional ability as reported by study partner/informant (score range (0-30, low is better). We will measure change from baseline after 4, 8, and 12 weeks of treatment.
Time Frame
Baseline, 4 weeks, 8 weeks and 12 weeks
Title
Repeated Battery for the Assessment of Neuropsychological Status
Description
Evaluate the effect of tacrolimus on several domains of cognitive function (score range 40-160, higher is better). We will measure change from baseline after 4, 8, and 12 weeks of treatment.
Time Frame
Baseline, 4 weeks, 8 weeks and 12 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
55 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Study subjects meeting all of the following criteria will be allowed to enroll in the study:
Age 55-85 inclusive, male or female.
Diagnosis of MCI or dementia due to AD as shown by positive AD biomarker (CSF or neuroimaging).
Education level, English language skills and literacy indicates subject will be able to complete all assessments.
Willing and able to complete all assessment and study procedures, including phlebotomies, lumbar punctures, MRIs, neurocognitive testing.
Subject has a study partner with at least two days of contact per week and willingness to assist with subject's research activities.
If on cholinesterase inhibitor and/or memantine, doses are stable for 3 months prior to baseline.
Exclusion Criteria:
Subjects meeting any of the following criteria during the screening evaluation will be excluded:
Allergy or hypersensitivity to tacrolimus.
Any specific CNS disease other than suspected AD, such as major clinical stroke, brain tumor, normal pressure hydrocephalus, multiple sclerosis, significant head trauma with persistent neurological of cognitive deficits or complaints, Parkinson's disease, frontotemporal dementia, and/or other neurodegenerative diseases.
Any significant systemic illness or clinically significant unstable medical condition that could affect subject safety or compliance with the study; including but not limited to any active infection, active malignancy except non-melanomatous skin cancers, cirrhosis, active hepatitis, uncontrolled diabetes (A1c >8), AIDS, common variable immunodeficiency, conditions treated with biologics, uncontrolled hypertension, chronic kidney disease with an eGFR <45 ml/min, Platelets < 100K, Hgb <9.
History of alcohol or other substance abuse or dependence with the past two years.
Major active psychiatric illness (e.g. depression, bipolar disorder, obsessive compulsive disorder, schizophrenia) within the previous year.
Current suicidal ideation or history of suicide attempt.
Contraindications to undergo MRI studies:
History of a cardiac pacemaker or pacemaker wires,
Metallic particles in the body,
Vascular clips in the head,
Prosthetic heart valves, or
Severe claustrophobia impeding ability to participate in an imaging study.
MRI findings that show one or more of the following:
More than 4 incidental microhemorrhages,
Incidental lacunar infarcts with attributable signs or symptoms and with history of stroke,
Incidental meningiomas with attributable signs or symptoms, or
Newly recognized meningioma.
Laboratory abnormalities in B12, TSH, or other common laboratory parameters that may contribute to cognitive dysfunction.
Laboratory abnormalities in PT-INR, CBC, electrolytes, magnesium, LFTs, BUN, Cr or others, or abnormalities in ECG posing risk to treatment with tacrolimus.
Current use of medications with psychoactive properties (e.g., anticholinergics, antihistamines, antipsychotics, sedative hypnotics, anxiolytics) that may deleteriously affect cognition in the judgement of the investigator.
Current use of medications that interact with tacrolimus (protease inhibitors, macrolides, rifampin, barbiturates, phenytoin, or azoles).
Inability to avoid any dietary supplements that could interact with tacrolimus metabolism.
Inability to avoid grapefruit and grapefruit juice.
Use of other small molecule or device-based investigational agents one month prior to entry and for the duration of the trial; or participation in any immunotherapy clinical trial within three months prior to baseline visit.
Discontinuation of cholinesterase inhibitor or memantine within one month (28 days) prior to baseline visit.
Females who are pregnant, lactating or of child-bearing potential
-
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
A Pilot Open Labeled Study of Tacrolimus in Alzheimer's Disease.
We'll reach out to this number within 24 hrs